CCL21 and cervical carcinoma: In a recent study, Moeini et al. investigated whether the therapeutic effect of a DNA vaccine, which codes for the human papillomavirus type 16 (HPV-16) E7, through the combined application of an immune checkpoint blockade against the programmed death-1 (PD-1) signaling pathway and secondary lymphoid tissue chemokine (SLC), also known as the CCL21 adjuvant, can be enhanced in a mouse cervical carcinoma model [83].